Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
(Thomson Reuters ONE) -
UTRECHT, The Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that data from a Phase 1/2
study of MCLA-128 for the treatment of metastatic breast cancer will be
presented in a poster session at the American Society of Clinical Oncology
(ASCO) Annual Meeting, which will be held on June 2-6, 2017 in Chicago,
Illinois.
Details of the poster presentation are as follows:
Title: First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific
antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in
HER2+ metastatic breast cancer (MBC)
Abstract Number: 2522
Poster Session: Developmental Therapeutics-Clinical Pharmacology and
Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 AM-11:30 AM CT
About MCLA-128
MCLA-128 is designed to block HER3/heregulin dependent tumor growth and survival
as well as enhance immune-mediated killing of tumors. MCLA-128 employs a 'dock
and block' mechanism in which the mode of HER2 receptor binding orientates the
HER3 binding arm to effectively block oncogenic signaling through the HER2:HER3
heterodimer even under high heregulin concentrations. In addition, MCLA-128 is
engineered for enhanced ADCC in order to recruit and activate immune effector
cells to directly kill the tumor.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe
as a potential treatment for HER2-expressing solid tumors. Merus' second
bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2
clinical trial in patients with acute myeloid leukemia. The Company also has a
pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem cells
and is being developed as a potential treatment for colorectal cancer and other
solid tumors, and Biclonics® designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
Forward Looking Statement
Except for the historical information set forth herein, this press release
contains predictions, estimates and other forward-looking statements, including
without limitation statements regarding: the impact of the collaboration on
Merus' finances and clinical development, whether any of the programs under the
collaboration will be successful; and whether and when Merus will receive any of
the expected or potential payments under the collaboration and the amounts of
such payments to Merus. These forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ materially from our
expectations, including unanticipated developments in and risks related to:
research and development efforts related to the collaboration programs; the
clinical development process, which is expensive and unpredictable; the
possibility that results of clinical trials may be unsuccessful or insufficient
to meet applicable regulatory standards or warrant continued development; other
market or economic factors; unanticipated delays; Merus' ability to compete
against parties with greater financial or other resources; Merus' ability to
commercialize and market its products, if approved; greater than expected
expenses; and the other important factors detailed in Merus' final prospectus
filed with the Securities and Exchange Commission, or SEC, on May 20, 2016
relating to our Registration Statement on Form F-1, and its other reports filed
with the SEC. Merus disclaims any intent or obligation to update these forward-
looking statements. These forward-looking statements should not be relied upon
as representing Merus' views as of any date subsequent to the date of this press
release.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza(at)argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly(at)argotpartners.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 537509
Anzahl Zeichen: 5359
contact information:
Town:
Utrecht
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 154 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Merus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
